Lateral Single-Position surgery and Surgical Intelligence™ take center stage at conference
SAN DIEGO – April 24, 2018 – NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced the Company is a sponsor of the American Association of Neurological Surgeons (AANS) Annual Scientific meeting being held April 28-May 2, 2018, in New Orleans, at the Earnest N. Morial Convention Center. NuVasive will host a hands-on workshop featuring the latest advances in Lateral Single-Position surgery, technology to reduce OR radiation and developments in 3D-printed implants.
The NuVasive Industry Lunch and Learn Workshop, Single-Position Lateral Surgery Solutions to Treat L4-S1, Featuring Advanced 3D-Printed Implants and LessRay® Radiation Emission Reduction Technology, by Kaveh Khajavi, M.D., Robert Issacs, M.D. and Juan Uribe, M.D., will take place on Monday, April 30 from 1:10-1:55 p.m. in Room 272-273. For more information, visit the AANS Program Schedule.
“The interactive workshop provides a forum to discover our commitment to Safer, Faster and Smarter surgery through Surgical Intelligence as well as our leadership position in Lateral Single-Position surgery and how it fits in with our industry-leading lateral procedural solutions,” said Matt Link, executive vice president, strategy, technology and corporate development for NuVasive. “Lateral Single-Position benefits include reducing the number of times a patient has to be repositioned for greater OR efficiency. Attendees will hear directly from early adopters of the technology and also learn what NuVasive is doing to incorporate advanced materials into its surgical implants and how Surgical Intelligence includes proactively combatting radiation exposure in the OR with LessRay technology.”
Additionally, AANS attendees can visit NuVasive Booth #529 to experience the latest innovative spine solutions and systems firsthand from the NuVasive team of experts and meet NFL great and NuVasive spokesperson Archie Manning. The College Hall of Fame and former NFL Pro Bowl quarterback will discuss his firsthand experience with the life-changing NuVasive XLIF® procedure at the Lunch and Learn and in the booth on Monday, April 30. Manning continues to proudly share his personal story of how the XLIF spine procedure changed his life by restoring height and stability to the collapsed disc space on the left side of his lumbar spine. XLIF is the leading lateral spine procedure, supported by over 10 years of clinical evidence.
Individual NuVasive booth stations will focus on a variety of spine solutions, including Lateral Single-Position Surgery, Surgical Intelligence, Advanced Materials Science™, Cervicothoracic and TLIF.
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally-integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company’s portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With over $1 billion in revenues, NuVasive has an approximate 2,400 person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA® platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.